

## HR 9297

### Pre-Approval Information Exchange Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Nov 15, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Nov 16, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/9297>

## Sponsor

**Name:** Rep. Guthrie, Brett [R-KY-2]

**Party:** Republican • **State:** KY • **Chamber:** House

## Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Nov 15, 2022
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Nov 15, 2022
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Nov 15, 2022
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Nov 15, 2022
Rep. Peters, Scott H. [D-CA-52]	D · CA		Nov 15, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 16, 2022

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.

## Summary (as of Nov 15, 2022)

### Pre-Approval Information Exchange Act of 2022

This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.

## **Actions Timeline**

---

- **Nov 16, 2022:** Referred to the Subcommittee on Health.
- **Nov 15, 2022:** Introduced in House
- **Nov 15, 2022:** Referred to the House Committee on Energy and Commerce.